124 related articles for article (PubMed ID: 1328923)
21. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
[TBL] [Abstract][Full Text] [Related]
22. Activity of spantide I and II at various tachykinin receptors and NK-2 tachykinin receptor subtypes.
Maggi CA; Patacchini R; Feng DM; Folkers K
Eur J Pharmacol; 1991 Jun; 199(1):127-9. PubMed ID: 1716573
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors.
McKnight AT; Maguire JJ; Elliott NJ; Fletcher AE; Foster AC; Tridgett R; Williams BJ; Longmore J; Iversen LL
Br J Pharmacol; 1991 Oct; 104(2):355-60. PubMed ID: 1665732
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity study of the C-terminal residue of MEN 10207 tachykinin antagonist.
Rovero P; Quartara L; Astolfi M; Patacchini R; Giachetti A; Maggi CA
Peptides; 1992; 13(1):207-8. PubMed ID: 1320265
[TBL] [Abstract][Full Text] [Related]
25. MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are potent tachykinin NK-2 receptor antagonists.
Maggi CA; Quartara L; Patacchini R; Giuliani S; Barbanti G; Turini D; Giachetti A
Regul Pept; 1993 Sep; 47(2):151-8. PubMed ID: 8234901
[TBL] [Abstract][Full Text] [Related]
26. Amastatin interferes with the antagonist properties of MEN 10,208 in the rabbit pulmonary artery but not in the hamster trachea.
Patacchini R; Maggi CA
Eur J Pharmacol; 1993 May; 236(1):31-7. PubMed ID: 8391454
[TBL] [Abstract][Full Text] [Related]
27. [125I]neurokinin A labels pharmacologically distinct populations of NK2 binding sites in hamster and rabbit urinary bladder.
Guard S; Pain D; Franks R; Watling KJ
Eur J Pharmacol; 1993 Mar; 232(2-3):287-90. PubMed ID: 8385619
[TBL] [Abstract][Full Text] [Related]
28. Role of C-terminal amidation on the biological activity of neurokinin A derivatives with agonist and antagonist properties.
Patacchini R; Quartara L; Rovero P; Goso C; Maggi CA
J Pharmacol Exp Ther; 1993 Jan; 264(1):17-21. PubMed ID: 8380857
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of three tachykinin receptors coupled to Ca++ signaling pathways in intestinal muscle cells.
Hellstrom PM; Murthy KS; Grider JR; Makhlouf GM
J Pharmacol Exp Ther; 1994 Jul; 270(1):236-43. PubMed ID: 8035320
[TBL] [Abstract][Full Text] [Related]
30. Tachykinin receptors in the small intestine of the cane toad (Bufo marinus): a radioligand binding and functional study.
Burcher E; Warner FJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):692-700. PubMed ID: 9686947
[TBL] [Abstract][Full Text] [Related]
31. Effect of several bicyclic peptide and cyclic pseudopeptide tachykinin NK2 receptor antagonists in the human isolated urinary bladder.
Giuliani S; Patacchini R; Lazzeri M; Benaim G; Turini D; Quartara L; Maggi CA
J Auton Pharmacol; 1996 Oct; 16(5):251-9. PubMed ID: 9023669
[TBL] [Abstract][Full Text] [Related]
32. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
[TBL] [Abstract][Full Text] [Related]
33. A pharmacological study with substance K: evidence for multiple types of tachykinin receptors.
Hunter JC; Maggio JE
Eur J Pharmacol; 1984 Oct; 105(1-2):149-53. PubMed ID: 6208041
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship study of R396, an NK2 tachykinin antagonist selective for the NK2B receptor subtype.
Rovero P; Astolfi M; Manzini S; Jukic D; Rouissi N; Maggi CA; Regoli D
Neuropeptides; 1992 Nov; 23(3):143-5. PubMed ID: 1335133
[TBL] [Abstract][Full Text] [Related]
35. Neurokinin receptor subtypes characterized by biological assays.
Regoli D; Nguyen QT; Jukic D
Life Sci; 1994; 54(26):2035-47. PubMed ID: 8208061
[TBL] [Abstract][Full Text] [Related]
36. Cyclic peptides as selective tachykinin antagonists.
Williams BJ; Curtis NR; McKnight AT; Maguire JJ; Young SC; Veber DF; Baker R
J Med Chem; 1993 Jan; 36(1):2-10. PubMed ID: 7678430
[TBL] [Abstract][Full Text] [Related]
37. Actinomycin D is a competitive and selective antagonist at NK2 tachykinin receptors.
Patacchini R; Astolfi M; Brown MC; Maggi CA
Neuropeptides; 1991 Oct; 20(2):109-14. PubMed ID: 1665895
[TBL] [Abstract][Full Text] [Related]
38. [125I]His-neurokinin A binds selectively to NK2 receptors of the B-type in rat small intestine smooth muscle membranes.
Brown MC; Biagi M; Renzetti AR; Rovero P; Criscuoli M; Mizrahi J
Eur J Pharmacol; 1992 Oct; 227(2):163-71. PubMed ID: 1330648
[TBL] [Abstract][Full Text] [Related]
39. Isolation and pharmacological characterization of a hamster urinary bladder neurokinin A receptor cDNA.
Aharony D; Little J; Thomas C; Powell S; Berry D; Graham A
Mol Pharmacol; 1994 Jan; 45(1):9-19. PubMed ID: 8302285
[TBL] [Abstract][Full Text] [Related]
40. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
Meini S; Bellucci F; Catalani C; Cucchi P; Patacchini R; Rotondaro L; Altamura M; Giuliani S; Giolitti A; Maggi CA
Eur J Pharmacol; 2004 Mar; 488(1-3):61-9. PubMed ID: 15044036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
